Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Mina Tanaka

Internal Medicine Shiprock, NM Medical Doctor

NPI 1740661248 CMS profile 1323649

US Hwy 491 North, --, Shiprock, NM 87420

Open in the dashboard

General payments

$869

27 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Mina Tanaka of Shiprock, NM is reported in the CMS Open Payments database as having received $869 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $63 4
2019 General $806 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mina Tanaka
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mina Tanaka were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mina Tanaka Internal Medicine median Middle half National median
2019 $806 $159 $48–$570 $163
2020 $63 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Gilead Sciences, Inc. $335 12 payments
  2. AstraZeneca Pharmaceuticals LP $186 5 payments
  3. Indivior Inc. $164 3 payments
  4. AbbVie, Inc. $134 4 payments
  5. ViiV Healthcare Company $23 1 payment
  6. Merck Sharp & Dohme Corporation $14 1 payment
  7. Neurocrine Biosciences, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $869 27 payments
Products named General payments · program years 2019–2020
  1. FARXIGA $168 4 payments
  2. SUBLOCADE $164 3 payments
  3. MAVYRET $134 4 payments
  4. Biktarvy $69 1 payment
  5. Truvada $61 1 payment
  6. DOVATO $23 1 payment
  7. PIFELTRO $14 1 payment
  8. DELSTRIGO $14 1 payment
  9. ISENTRESS $14 1 payment
  10. INGREZZA $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

429

Median for Internal Medicine: 777

Drug cost

$98,820

Median for Internal Medicine: $73,373

Branded share of claims

39.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 50 $39,405
Ozempic Semaglutide Brand 31 $30,053
Eliquis Apixaban Brand 25 $22,160
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $2,471
Synthroid Levothyroxine Sodium Brand 15 $1,514
Atorvastatin Calcium Generic 46 $1,031
Gabapentin Generic 24 $442
Metformin Hcl Er Metformin Hcl Brand 30 $351
Amitriptyline Hcl Generic 15 $266
Lisinopril Generic 54 $244

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$21,963

Medicare's payments for the services billed

Medicare patients

158

Average age 73

Services billed

291

91 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Arthritis 45%
Chronic kidney disease 24%
Ischemic heart disease 23%
Heart failure 20%
Osteoporosis 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record